The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

The Contour Next One Blood Glucose Monitor is a bestseller and a budget-friendly at under $35 for the test kit. The blood ...

BofA Securities maintained a Buy rating on DexCom (NASDAQ:DXCM) shares, with a steady price target of $90.00. The firm's analysts suggest the current market movement presents an appealing opportunity ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its Lingo device - and ...

system. Eversense 365 is well-suited to address common limitations of AID systems and the companies are advancing partnership discussions with various pump manufacturers. The Eversense Continuous ...